@article{2999593,
    title = "Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy",
    author = "Terpos, E. and Gavriatopoulou, M. and Ntanasis-Stathopoulos, I. and Briasoulis, A. and Gumeni, S. and Malandrakis, P. and Papanagnou, E.-D. and Migkou, M. and Kanellias, N. and Kastritis, E. and Trougakos, I.P. and Dimopoulos, M.A.",
    journal = "Blood advances",
    year = "2022",
    volume = "139",
    number = "9",
    pages = "1409-1412",
    publisher = "Elsevier B.V.",
    doi = "10.1182/blood.2021014989",
    keywords = "bnt 162b 2;  immunological antineoplastic agent;  immunomodulating agent;  lenalidomide;  neutralizing antibody;  proteasome inhibitor;  tozinameran, adult;  aged;  antibody production;  antibody response;  antibody titer;  cancer immunotherapy;  controlled study;  coronavirus disease 2019;  female;  human;  humoral immunity;  Letter;  major clinical study;  male;  multiple myeloma;  repeated drug dose;  Severe acute respiratory syndrome coronavirus 2;  vaccination"
}